Home Watchlists Portfolios Indices Forex Futures Comparisons Alerts Screeners Scans Charts Settings

AtriCure (NASDAQ:ATRC) Stock Rating Lowered by Zacks Investment Research

  • Source: TechNewsObserver - - Read: 0



    AtriCure (NASDAQ:ATRC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

    According to Zacks, “AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. “

    ATRC has ...



    Read Full News: https://technewsobserver.com/news/2019/10/10/atricure-nasdaqatrc-stock-rating-lowered-by-zacks-investment-research.html

Log in to reply